Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.

Karim Fizazi,Alfredo Rodríguez Antolín,Susan Feyerabend,Andrew Protheroe,Suneel Mundle,Boris Yakovlevich Alekseev,Giri Sulur,Nobuaki Matsubara,Luis Enrique Fein,Susan Li,Kim N Chi,Youn C Park,Peter De Porre,Mustafa Ozguroglu,Namphuong Tran

doi:10.1200/jco.2018.36.15_suppl.5023

Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.

Karim Fizazi, Alfredo Rodríguez Antolín + Show 13 more

https://doi.org/10.1200/jco.2018.36.15_suppl.5023

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2018
Citations: 2

Affiliation: Institut Polytechnique de Paris, University of Paris-Sud, Institut Gustave Roussy, Hospital Universitario 12 De Octubre, University of Oxford, Janssen (United States), Cancer Research Institute, P.A. Hertzen Moscow Oncology Research Institute, National Cancer Center Hospital East, Instituto de Oncología de Rosario, Janssen (Belgium), Istanbul University

#Significant Improvements In OS #Improvements In OS + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

5023Background: The LATITUDE study in pts with NDx-HR mCNPC found significant improvements in OS, rPFS, and all secondary end points, including pt-reported outcomes when combining AA + P with andro...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.